• Jobs
  • Startups
  • Hire
LoginSign up

Superluminal Medicines

Superluminal Medicines has 7 open roles, 4 posted in the last 30 days. Stated pay range: $75k – $357k a year. Funding stage: Series B. Last round: Sep 3, 2026.

Open roles

  • Superluminal Medicines logo
    Director, Corporate Development & Strategy

    Superluminal Medicines

    • Boston, MA
    • Director / Executive
    • $214k–$246k
    Greenhouse
    Posted 2d ago
  • Superluminal Medicines logo
    Senior Manager, Technical Accounting & Financial Reporting

    Superluminal Medicines

    • Boston, MA
    • Senior
    • $165k–$195k
    Greenhouse
    Posted 10d ago
  • Superluminal Medicines logo
    Staff Engineer, Research Informatics and AI

    Superluminal Medicines

    • Boston, MA
    • Staff / Lead
    • $191k–$219k
    Greenhouse
    Posted 21d ago
  • Superluminal Medicines logo
    Vice President, Head of Legal

    Superluminal Medicines

    • Boston, MA
    • Director / Executive
    • $315k–$357k
    Greenhouse
    Posted 29d ago
  • Superluminal Medicines logo
    Sr. Scientist, In-Vivo Pharmacology

    Superluminal Medicines

    • Boston, MA
    • Senior
    • $149k–$169k
    Greenhouse
    Posted 37d ago
  • Superluminal Medicines logo
    Research Associate, Discovery Biology

    Superluminal Medicines

    • Boston, MA
    • On-site · Junior
    • $75k–$100k
    Greenhouse
    Posted 46d ago
Show all roles

About

Superluminal Medicines logo

Superluminal Medicines

Superluminal Medicines develops small-molecule therapeutics using generative biology, chemistry, machine learning, and proprietary data infrastructure. Its Hyperloop platform integrates structure-based drug discovery, computational approaches, and experimental research to identify and validate drug candidates. The company focuses on GPCR-targeted treatments, particularly for cardiometabolic diseases, obesity, and rare genetic conditions.

Series BRecently raised
HQBoston, United States
Size11–50 employees
IndustryBiotechnology Research
Unlock human wisdom
ThesisTermsPrivacy
Funding
  • Series B · Sep 3, 2026
Investors
BVF PartnersCatalio Capital ManagementDeep Track CapitalInsight PartnersRA Capital Management

Claim superluminalrx.com

Work at superluminalrx.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.